Michel Demeule1
Jean-Christophe Currie1
Cyndia Charfi1Alain Zgheib2Isabelle Cousineau2Véronique Lullier2Richard Béliveau2
Christian Marsolais1
Borhane Annabi2*- 1Theratechnologies Inc., Montréal, QC, Canada
- 2Laboratoire d’Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montréal, QC, Canada
A Corrigendum on:
Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing
By Demeule M, Currie J-C, Charfi C, Zgheib A, Cousineau I, Lullier V, Béliveau R, Marsolais C and Annabi B (2024) Front. Immunol. 15:1355945. doi: 10.3389/fimmu.2024.1355945
In the published article, there was an error in Figures 1A, C as published. In the original Figure 1A: The colored text related to the color-coded dots underneath the x-axis was not aligned. In the original Figure 1C: The small blue box legends needed to be removed from the inserts of the first line of pictures. The corrected Figures 1A, C and its caption “Figure 1 Sustained and prolonged antitumor activity of TH1902 in an immunosuppressed MDA-MB-231 TNBC-derived xenograft model.” appear below.
Figure 1
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: peptide-drug conjugate, checkpoint inhibitor, docetaxel, sortilin, STING, immune tumor microenvironment, PD-L1
Citation: Demeule M, Currie J-C, Charfi C, Zgheib A, Cousineau I, Lullier V, Béliveau R, Marsolais C and Annabi B (2024) Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing. Front. Immunol. 15:1389603. doi: 10.3389/fimmu.2024.1389603
Received: 21 February 2024; Accepted: 22 February 2024;
Published: 28 February 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Demeule, Currie, Charfi, Zgheib, Cousineau, Lullier, Béliveau, Marsolais and Annabi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Borhane Annabi, annabi.borhane@uqam.ca